Hope vs hype: where are we in type 1 diabetes?

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations

Abstract

Much progress has been made in type 1 diabetes research. Biological replacement of islet function has been achieved with pancreas transplantation and with islet transplantation. In the future, human embryonic stem cells and/or induced pluripotent stem cells may offer a potentially unlimited source of cells for islet replacement. Another potential strategy is to induce robust beta cell replication so that regeneration of islets can be achieved. Immune interventions are being studied with the hope of arresting the type 1 diabetes disease process to either prevent the disease or help preserve beta cell function. Mechanical replacement of islet cell function involves the use of glucose sensor-controlled insulin infusion systems. As all of these avenues are pursued, headlines often overstate the case, thus hyping any given advance, which provides enormous hope for patients and families seeking a cure for type 1 diabetes. Often, however, it is an animal study or a pilot trial that is being described. The reality is that translation to successful trials in human beings may not be readily achievable. This article discusses both the hype and the hopes in type 1 diabetes research.

Original languageEnglish (US)
Pages (from-to)509-516
Number of pages8
JournalDiabetologia
Volume61
Issue number3
DOIs
StatePublished - Mar 1 2018

Keywords

  • Automated insulin delivery
  • Immune intervention
  • Islet regeneration
  • Islet replacement therapy
  • Review
  • Stem cells
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint

Dive into the research topics of 'Hope vs hype: where are we in type 1 diabetes?'. Together they form a unique fingerprint.

Cite this